Coldstream Capital Management Inc. Purchases 21,765 Shares of Zoetis Inc. (NYSE:ZTS)

Coldstream Capital Management Inc. lifted its position in Zoetis Inc. (NYSE:ZTS) by 224.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 31,452 shares of the company’s stock after buying an additional 21,765 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Zoetis were worth $5,453,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in ZTS. Norges Bank acquired a new position in shares of Zoetis in the fourth quarter valued at $980,646,000. Price T Rowe Associates Inc. MD raised its stake in Zoetis by 31.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after acquiring an additional 3,244,074 shares in the last quarter. Sarasin & Partners LLP raised its stake in Zoetis by 546.3% during the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after acquiring an additional 1,904,899 shares in the last quarter. Swedbank AB acquired a new position in Zoetis during the first quarter worth $210,815,000. Finally, Public Employees Retirement Association of Colorado acquired a new position in Zoetis during the fourth quarter worth $242,757,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $189.66 on Tuesday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The stock has a market cap of $85.93 billion, a price-to-earnings ratio of 36.94, a P/E/G ratio of 2.90 and a beta of 0.88. The business’s 50-day simple moving average is $181.60 and its 200 day simple moving average is $174.36.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the previous year, the business posted $1.41 EPS. Zoetis’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, research analysts anticipate that Zoetis Inc. will post 5.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ZTS shares. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Stifel Nicolaus restated a “buy” rating and issued a $200.00 target price on shares of Zoetis in a research note on Tuesday, August 27th. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus target price of $217.11.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.